GlaxoSmithKline Pharmaceuticals Limited (IN:GLAXO)
:GLAXO
GLAXO Stock Chart & Stats
₹2483.35
-₹2.55(-0.12%)
At close: 4:00 PM EST
₹2483.35
-₹2.55(-0.12%)
Day’s Range― - ―
52-Week Range₹2,218.00 - ₹3,515.95
Previous CloseN/A
Volume25.42K
Average Volume (3M)1.83K
Market Cap
₹397.54B
Enterprise Value₹390.41B
Total Cash (Recent Filing)₹20.61B
Total Debt (Recent Filing)₹357.10M
Price to Earnings (P/E)35.4
Beta0.72
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.16%
Share Statistics
EPS (TTM)16.70
Shares Outstanding169,406,040
10 Day Avg. Volume1,472
30 Day Avg. Volume1,831
Financial Highlights & Ratios
PEG Ratio0.89
Price to Book (P/B)24.29
Price to Sales (P/S)12.72
P/FCF Ratio37.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)68.48
Revenue Forecast (FY)₹42.76B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExtremely low leverage and significant liquidity give the company durable financial flexibility. This allows funding of local manufacturing, R&D, tender participation and working capital without external borrowing, reducing refinancing risk and supporting continuity across regulatory or pricing cycles.
Free Cash Flow GenerationVery strong free cash flow and operating cash conversion indicate high cash-generation quality. That enables sustainable dividends, reinvestment in commercialization or manufacturing, and selective M&A without stressing the balance sheet, improving resilience against cyclical tender timing.
High Profitability & MarginsRobust gross and net margins combined with consistent revenue growth signal durable pricing power and operational efficiency. High EBIT/EBITDA margins support reinvestment and buffer margin compression from regulatory pricing or input-cost swings, sustaining core profitability over months ahead.
Bears Say
Opaque Product/Segment DisclosureLack of disclosed product and segment detail reduces visibility into revenue drivers, product concentration, patent or lifecycle risk and tender dependencies. That opacity makes it harder to assess long-term sustainability of sales and the impact of any single product or market on future performance.
Exposure To Pricing Controls & Tender SalesStructural reliance on public tenders and pricing regulation can cap price upside and make revenues lumpy. Over the medium term, centralized procurement and price controls can compress margins or force higher volumes to maintain revenue, increasing sensitivity to competitive bidding cycles.
Limited Investor CommunicationAbsence of earnings call disclosures and corporate-event detail limits insight into management's strategy, guidance and execution plans. This persistent lack of transparency hinders assessment of capital allocation, pipeline progress and responsiveness to market or regulatory changes over coming months.
GlaxoSmithKline Pharmaceuticals Limited News
GLAXO FAQ
What was GlaxoSmithKline Pharmaceuticals Limited’s price range in the past 12 months?
GlaxoSmithKline Pharmaceuticals Limited lowest stock price was ₹2218.00 and its highest was ₹3515.95 in the past 12 months.
What is GlaxoSmithKline Pharmaceuticals Limited’s market cap?
GlaxoSmithKline Pharmaceuticals Limited’s market cap is ₹397.54B.
When is GlaxoSmithKline Pharmaceuticals Limited’s upcoming earnings report date?
GlaxoSmithKline Pharmaceuticals Limited’s upcoming earnings report date is May 19, 2026 which is in 42 days.
How were GlaxoSmithKline Pharmaceuticals Limited’s earnings last quarter?
GlaxoSmithKline Pharmaceuticals Limited released its earnings results on Feb 09, 2026. The company reported ₹16.7 earnings per share for the quarter, the consensus estimate of ₹16.7 by ₹0.
Is GlaxoSmithKline Pharmaceuticals Limited overvalued?
According to Wall Street analysts GlaxoSmithKline Pharmaceuticals Limited’s price is currently Overvalued.
Does GlaxoSmithKline Pharmaceuticals Limited pay dividends?
GlaxoSmithKline Pharmaceuticals Limited pays a Annually dividend of ₹42 which represents an annual dividend yield of 2.16%. See more information on GlaxoSmithKline Pharmaceuticals Limited dividends here
What is GlaxoSmithKline Pharmaceuticals Limited’s EPS estimate?
GlaxoSmithKline Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GlaxoSmithKline Pharmaceuticals Limited have?
GlaxoSmithKline Pharmaceuticals Limited has 169,406,040 shares outstanding.
What happened to GlaxoSmithKline Pharmaceuticals Limited’s price movement after its last earnings report?
GlaxoSmithKline Pharmaceuticals Limited reported an EPS of ₹16.7 in its last earnings report, expectations of ₹16.7. Following the earnings report the stock price went up 1.012%.
Which hedge fund is a major shareholder of GlaxoSmithKline Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:GLAXO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-infective, respiratory, dermatology, nutrition, gastrointestinal, and rare diseases; and consumer healthcare products. It provides its product under the Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact, Tenovate, Flutivate, Physiogel, Zimig, Cobadex CZS, Infanrix Hexa, Synflorix, Supacef, Havrix, Menveo, Boostrix, Fluarix Tetra, Varilrix, Nucala, and Trelegy Ellipta brands. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.
Technical Analysis
Cipla Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Lupin Limited
―
Sun Pharmaceutical Industries Limited
―
Torrent Pharmaceuticals Ltd
―